Levonadifloxacin

Levonadifloxacin (trade name Emrok) is an antibiotic drug of the fluoroquinolone class. Chemically, it is the (S)-enantiomer of the racemic drug nadifloxacin.

It is approved in India for the treatment of skin and soft tissue infections of Gram-positive bacteria. It is also being studied for potential use against resistant strains of bacteria including Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis.

Levonadifloxacin has poor oral bioavailability. A prodrug of levonadifloxacin with high oral bioavailability, alalevonadifloxacin, has been developed to mitigate this problem.